Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Show more

3027 Townsgate Road, Westlake Village, CA, 91361, United States

https://www.arcutis.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

2.822B

52 Wk Range

$11.86 - $31.77

Previous Close

$22.75

Open

$23.12

Volume

1,135,863

Day Range

$22.56 - $23.20

Enterprise Value

2.714B

Cash

221M

Avg Qtr Burn

N/A

Insider Ownership

1.71%

Institutional Own.

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic dermatitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Atopic Dermatitis (Ages 2 to 5)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (roflumilast) Topical Foam 0.3% Details Plaque Psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Plaque psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (Roflumilast foam 0.3%) Details Seborrheic dermatitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream Details Plaque psoriasis (Ages 6 to 11)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (roflumilast) Cream 0.3% Details Plaque psoriasis (Ages 2 to 5)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE® (ARQ-151) topical roflumilast cream 0.05% Details Atopic dermatitis	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Hidradenitis Suppurativa	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Hidradenitis Suppurativa	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Vitiligo	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor) Details Vitiligo	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-234 Details Moderate to severe atopic dermatitis	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-252 (JAKi) Details Vitiligo	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-255 topical ivarmacitinib Details Alopecia areata	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARQ-252 (JAK1i) Details Skin disease/disorder, Eczema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.